MetaCap

Inhibikase Therapeutics Insider Trades

NASDAQ: IKTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.32+0.02 (+1.54%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
0 · $0
Sales
0 · $0
Shares bought / sold
0 / 0
Net activity
Net buying $0

Inhibikase Therapeutics insider activity

Over the last 12 months, Inhibikase Therapeutics insiders reported 5 transactions on SEC Form 4: 0 open-market purchases and 0 sales. The most recent filing shows BERMAN DENNIS N (Director) reporting a transaction in 21,854 shares at $1.26 on Jul 30, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put IKT's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

IKT insider transactions

Inhibikase Therapeutics insider transactions
DateInsiderTypeSharesValueFiling
Jul 30, 2026BERMAN DENNIS NDirectorOption exercise21,854$27.54KForm 4
Jul 29, 2026RA CAPITAL MANAGEMENT, L.P. & RA Capital Healthcare Fund LP & Kolchinsky Peter & Shah Rajeev M.10% Ownerother18,030,000—Form 4
Feb 21, 2026Cabell ChristopherPresident & Head of R&DDisposition338,282—Form 4
Feb 21, 2026Aurentz VincentDirectorDisposition255,299—Form 4
Feb 21, 2026Munshi AmitDirectorDisposition19,089—Form 4
Nov 21, 2025Sands Capital Life Sciences Pulse Fund II, L.P. & Sands Capital Alternatives, LLC & SANDS FRANK M.10% OwnerBuy2,068,965$3.00MForm 4
Feb 21, 2025Munshi AmitDirectorAward57,265—Form 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related